Mid-Day Gainers From New Year's Eve 2014: NephroGenex And Other Biopharma Stocks

NephroGenex Inc (NASDAQ: NRX) +212% - After hours Tuesday, the company announced positive results from the QT study of Pyridorin.

RedHill Biopharma Ltd - ADR (NASDAQ: RDHL) +36% - Shares are higher following the company’s announcement that the United Kingdom has validated its marketing authorization application for its Bekinda drug.

Meadowbrook Insurance Group, Inc. (NYSE: MIG) +19% Fosum International announced it will acquire Meadowbrook for $8.65 per share or $433 million.

Cytokinetics, Inc. (NASDAQ: CYTK) +15% - Shares continue higher following a price target increase to $18 per share by Roth Capital analysts.

Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR) +13% - The company provided an update on its TKM-PLK1 Phase I/II clinical study.